Market Cap 407.00M
Revenue (ttm) 0.00
Net Income (ttm) -66.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 555,947
Avg Vol 4,704,298
Day's Range N/A - N/A
Shares Out 180.09M
Stochastic %K 26%
Beta 0.90
Analysts Strong Sell
Price Target $10.00

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8099
Address:
80 Guest Street, Suite 601, Boston, United States
TBROS1898
TBROS1898 Jul. 14 at 9:06 PM
$CMPX da fuq?
0 · Reply
Millionaire11
Millionaire11 Jul. 14 at 5:56 PM
$CMPS im about 95% sure this is being confused with $CMPX and that could be hindering its value. I dont mind gives me time to load up on $CMPS while the market catches up to whats going on.
1 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 14 at 5:08 PM
$CMPX well hopefully it’s doing this same dance next Friday. I’ll gladly grab a nice chunk.
0 · Reply
ajmrtxl
ajmrtxl Jul. 14 at 2:24 PM
$CMPX 's latest squeeze play
0 · Reply
TBROS1898
TBROS1898 Jul. 14 at 1:55 PM
$CMPX pegging the ol 2.20$ I c
2 · Reply
TBROS1898
TBROS1898 Jul. 14 at 1:28 PM
$CMPX premarket up then 3 mins before (red) 🙄
0 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 13 at 10:36 PM
$CMPX Notice the suppress and grab shares method going on. It’s not falling. Just bouncing.
0 · Reply
wanderlust222
wanderlust222 Jul. 13 at 8:39 PM
$CMPX Picked up another 5k at 2.2 🤷
0 · Reply
TBROS1898
TBROS1898 Jul. 13 at 6:31 PM
$CMPX wtf happened here today? Insiders/tutes hold majority shares
3 · Reply
TBROS1898
TBROS1898 Jul. 13 at 4:45 PM
$CMPX and cue the slow creep back to break even today 😉
1 · Reply
Latest News on CMPX
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)

2026-05-05T12:13:40.000Z - 2 months ago

Compass Therapeutics reports Q1 EPS (10c), consensus (10c)


Compass Therapeutics Earnings release: Q1 2026

May 5, 2026, 7:30 AM EDT - 2 months ago

Compass Therapeutics Earnings release: Q1 2026


Compass Therapeutics Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 2 months ago

Compass Therapeutics Quarterly report: Q1 2026


Compass Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Proxy statement: Proxy filing


Compass Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Proxy statement: Proxy filing


Compass Therapeutics Transcript: Study update

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Transcript: Study update


Compass Therapeutics Press release: Study update

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Press release: Study update


Compass Therapeutics Slides: Study update

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Compass Therapeutics Slides: Study update


Compass Therapeutics reports Q4 EPS (9c), consensus (9c)

2026-03-05T12:38:02.000Z - 4 months ago

Compass Therapeutics reports Q4 EPS (9c), consensus (9c)


Compass Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 7:30 AM EST - 4 months ago

Compass Therapeutics Earnings release: Q4 2025


Compass Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:30 AM EST - 4 months ago

Compass Therapeutics Annual report: Q4 2025


Compass Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:30 AM EST - 4 months ago

Compass Therapeutics Annual report: Q4 2025


Compass Therapeutics Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 4 months ago

Compass Therapeutics Slides: Corporate presentation


Compass Therapeutics initiated with a Buy at Craig-Hallum

2026-02-13T13:15:26.000Z - 5 months ago

Compass Therapeutics initiated with a Buy at Craig-Hallum


Compass Therapeutics Slides: Corporate presentation

Jan 7, 2026, 7:00 AM EST - 6 months ago

Compass Therapeutics Slides: Corporate presentation


Compass Therapeutics provides corporate update

2026-01-06T13:36:59.000Z - 6 months ago

Compass Therapeutics provides corporate update


Compass Therapeutics Provides Corporate Update

Jan 6, 2026, 8:00 AM EST - 6 months ago

Compass Therapeutics Provides Corporate Update


Compass Therapeutics Announces Key Leadership Appointments

Jan 5, 2026, 8:00 AM EST - 6 months ago

Compass Therapeutics Announces Key Leadership Appointments


Compass Therapeutics files $400M mixed securities shelf

2025-12-30T21:10:54.000Z - 7 months ago

Compass Therapeutics files $400M mixed securities shelf


Compass Therapeutics Registration statement: Registration Filing

Dec 30, 2025, 7:00 AM EST - 7 months ago

Compass Therapeutics Registration statement: Registration Filing


Compass Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 8 months ago

Compass Therapeutics Slides: Corporate Presentation


Compass Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 8 months ago

Compass Therapeutics Earnings release: Q3 2025


Compass Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 8 months ago

Compass Therapeutics Quarterly report: Q3 2025


Compass Therapeutics Announces Proposed Public Offering

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Compass Therapeutics Announces Proposed Public Offering


Compass Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Earnings Call Transcript: Q2 2025


Compass Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Quarterly report: Q2 2025


Compass Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Earnings release: Q2 2025


Compass Therapeutics Slides: Corporate Presentation

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Compass Therapeutics Slides: Corporate Presentation


Compass Therapeutics Slides: Investor Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Compass Therapeutics Slides: Investor Presentation


Compass Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Earnings release: Q1 2025


Compass Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Quarterly report: Q1 2025


Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Transcript: Study Update

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Transcript: Study Update


Compass Therapeutics Slides: Study Update

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Slides: Study Update


Compass Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Annual report: Q4 2024


Compass Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Earnings release: Q4 2024


Compass Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compass Therapeutics Quarterly report: Q3 2024


Compass Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compass Therapeutics Earnings release: Q3 2024


Compass Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Quarterly report: Q2 2024


Compass Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Earnings release: Q2 2024


Compass Therapeutics Slides: Corporate Presentation

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Compass Therapeutics Slides: Corporate Presentation


Compass Therapeutics Proxy statement: Proxy Filing

May 29, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Announces CEO Transition

May 28, 2024, 4:10 PM EDT - 2 years ago

Compass Therapeutics Announces CEO Transition


Compass Therapeutics Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Compass Therapeutics Quarterly report: Q1 2024


Compass Therapeutics Earnings release: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Compass Therapeutics Earnings release: Q1 2024


Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Proxy statement: Proxy Filing


Compass Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Earnings release: Q4 2023


Compass Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Annual report: Q4 2023


Compass Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Compass Therapeutics Quarterly report: Q3 2023


Compass Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Compass Therapeutics Earnings release: Q3 2023


Compass Therapeutics Quarterly report: Q2 2023

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Compass Therapeutics Quarterly report: Q2 2023


Compass Therapeutics Earnings release: Q2 2023

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Compass Therapeutics Earnings release: Q2 2023


TBROS1898
TBROS1898 Jul. 14 at 9:06 PM
$CMPX da fuq?
0 · Reply
Millionaire11
Millionaire11 Jul. 14 at 5:56 PM
$CMPS im about 95% sure this is being confused with $CMPX and that could be hindering its value. I dont mind gives me time to load up on $CMPS while the market catches up to whats going on.
1 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 14 at 5:08 PM
$CMPX well hopefully it’s doing this same dance next Friday. I’ll gladly grab a nice chunk.
0 · Reply
ajmrtxl
ajmrtxl Jul. 14 at 2:24 PM
$CMPX 's latest squeeze play
0 · Reply
TBROS1898
TBROS1898 Jul. 14 at 1:55 PM
$CMPX pegging the ol 2.20$ I c
2 · Reply
TBROS1898
TBROS1898 Jul. 14 at 1:28 PM
$CMPX premarket up then 3 mins before (red) 🙄
0 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 13 at 10:36 PM
$CMPX Notice the suppress and grab shares method going on. It’s not falling. Just bouncing.
0 · Reply
wanderlust222
wanderlust222 Jul. 13 at 8:39 PM
$CMPX Picked up another 5k at 2.2 🤷
0 · Reply
TBROS1898
TBROS1898 Jul. 13 at 6:31 PM
$CMPX wtf happened here today? Insiders/tutes hold majority shares
3 · Reply
TBROS1898
TBROS1898 Jul. 13 at 4:45 PM
$CMPX and cue the slow creep back to break even today 😉
1 · Reply
NFA_DYOR
NFA_DYOR Jul. 13 at 12:01 PM
$CMPX KOL Patient advocates
0 · Reply
GangsterX
GangsterX Jul. 11 at 2:47 AM
$FATE $CMPX $PEPG $CNTX $PMVP Looking good huh ? it will go up more... Relax and enjoy the run.. if i pick something, only big $$ in the pocket. Free $$ no need to sign up membership like others shix...
0 · Reply
NFA_DYOR
NFA_DYOR Jul. 10 at 8:40 PM
$CMPX 1. ORR - won 2. PFS - Won 3. OS - headlines says missed. There is no concrete evidence of win or loss especially if you debate before vs after cross over. Its simply confounded that might require confirmatory trial maybe 4. Thry have fortress of cash to run operations to 2028 5. Shorts have doubled down their positions because of headlines to 37 million shares shorted - over 25% of float. 6. I am more bulish on this one. I'll wait for Aug to see what institutional ownership looks like, whether they exited or added $GRI i am bearish on this one. Thry have under $10 million in hand, burning quick, about to start expensive phase 2b. An overhang dilution is there $IMVT i am bulish on this one. They are in revenue generating phase $SRPT they have foutress of cash but early phase and high burn rate. Only trading intraday $NVTS they have 36 months of runway cash in hand, they diluted more but at higher price.
0 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 10 at 7:45 PM
$CMPX This won’t cripple Compass in any way for Full Approval.
1 · Reply
Brandonswest
Brandonswest Jul. 10 at 7:41 PM
$CRBU little bit of late life here. As it should be. Looks alot like $CMPX today.
0 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 10 at 7:29 PM
$CMPX Full approval ? Tovecimig’s PFS Hazard Ratio of 0.44 is phenomenally strong. In oncology, any HR below 0.50 signifies that a drug cut the risk of tumor growth or death by more than half. Zelboraf (0.26) and Afinitor (0.33) had similarly dominant HRs, which forced the FDA to prioritize the clear delay in cancer progression over messy survival data. Like Erbitux and Afinitor, Compass is fighting a baseline control arm that offers dismal real-world outcomes (chemotherapy in this setting yields roughly a 5% response rate with rapid progression). When the alternative is failure, the FDA historically accepts lower absolute numbers (like a 17.1% ORR) because the comparative benefit is still a threefold improvement When Erbitux and Afinitor proved they could safely halt tumor progression in failed lines of therapy, they became multi-billion dollar foundational assets.
0 · Reply
Brandonswest
Brandonswest Jul. 10 at 5:28 PM
$CMPX ...and then that happened.
1 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 10 at 4:51 PM
$CMPX In 2weeks be fully loaded.
0 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 10 at 4:36 PM
$CMPX 1,000 shares for long term. Any shares over 1k will be for flipping
1 · Reply
Brandonswest
Brandonswest Jul. 10 at 2:50 PM
$CMPX one more day with early stage Pharma investments... amirite guys?
0 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 10 at 2:28 PM
$CMPX the confidence of Tom Schuetz + the major data being very significant is what’s keeping me here. ✅ if you want the big bucks expect to be here until 2030.
1 · Reply
TooMuchFinesse
TooMuchFinesse Jul. 10 at 1:58 PM
$CMPX The FDA is historically much more lenient with statistical anomalies (like alpha-adjusted p-values and crossover contamination) when dealing with rare, aggressive cancers that have no approved second-line therapies. Tovecimig more than tripled the tumor response rate (18% vs 5.3%) and cut the risk of disease progression by 56%. The clinical benefit is real, even if the secondary mathematical endpoints got muddy
0 · Reply